drugset / Trial / NCT01709747

Single-arm Study to Assess the Safety of Hydromorphone Hydrochloride by Intrathecal Administration

NCT01709747

Phase 3 Completed 364 enrolled Piramal Critical Care, Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety of hydromorphone hydrochloride administered by intrathecal delivery.

Timeline

Start
2013-06
Primary completion
2018-02
Completion
2018-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydromorphone Other / unclassified Intrathecal

Indications